Carroll Financial Associates’s Novavax NVAX Stock Holding History

Carroll Financial Associates’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$3K	Sell	25 -20	-44%	-$3.44K	﹤0.01%	1444
2021 Q3	$9K	Buy	45 +20	+80%	+$4.41K	﹤0.01%	1253
2021 Q2	$5K	Sell	25 -127	-84%	-$23.3K	﹤0.01%	1438
2021 Q1	$27K	Buy	+152	New	+$30.3K	﹤0.01%	932
2019 Q2	–	Sell	-27	Closed	–	–	1664
2019 Q1	$0	Buy	+27	New	+$852	﹤0.01%	1448
2015 Q3	–	Sell	-100	Closed	-$22K	–	1127
2015 Q2	$22K	Hold	100	–	–	﹤0.01%	542
2015 Q1	$17K	Hold	100	–	–	0.01%	448
2014 Q4	$15K	Buy	+100	New	+$10.5K	0.01%	431

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Carroll Financial Associates's NVAX Position: Q4 2021 in Review

Carroll Financial Associates reduced its Novavax (NVAX) stake by 44% in Q4 2021, selling an estimated $3.44K and leaving 25 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Carroll Financial Associates first reported a position in NVAX in Q4 2014 and has held it in 8 quarters since. The position peaked at $27K in Q1 2021. 430 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

Carroll Financial Associates held 25 shares of Novavax worth $3K as of Q4 2021.
Carroll Financial Associates sold 20 Novavax shares in Q4 2021, an estimated $3.44K.
Novavax made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1444 holding.
Carroll Financial Associates first reported a position in Novavax in Q4 2014 and has held it in 8 quarters since.
Carroll Financial Associates's Novavax position peaked at $27K in Q1 2021.
430 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.